Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Y Box Binding Protein 1 Inhibition as a Targeted Therapy for Ovarian Cancer

ABSTRACT: A azopodophyllotoxin small molecule, SU056, was identified as a novel inhibitor of Y Box Binding Protein 1 and may inhibit progression of ovarian cancer.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Sharon Pitteri

LAB HEAD: Sharon Pitteri

PROVIDER: PXD022332 | Pride | 2021-12-19

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Dhanir_TMT_CETSA_50056_01.raw	Raw
	Dhanir_TMT_CETSA_50056_02.raw	Raw
	Dhanir_TMT_CETSA_50056_03.raw	Raw
	Dhanir_TMT_Control_092719_01.raw	Raw
	Dhanir_TMT_Control_092719_02.raw	Raw

Items per page:

1 - 5 of 16

Publications

Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer.

Tailor Dhanir D Resendez Angel A Garcia-Marques Fernando Jose FJ Pandrala Mallesh M Going Catherine C CC Bermudez Abel A Kumar Vineet V Rafat Marjan M Nambiar Dhanya K DK Honkala Alexander A Le Quynh-Thu QT Sledge George W GW Graves Edward E Pitteri Sharon J SJ Malhotra Sanjay V SV

Cell chemical biology 20210312 8

Y box binding protein 1 (YB-1) is a multifunctional protein associated with tumor progression and the emergence of treatment resistance (TR). Here, we report an azopodophyllotoxin small molecule, SU056, that potently inhibits tumor growth and progression via YB-1 inhibition. This YB-1 inhibitor inhibits cell proliferation, resistance to apoptosis in ovarian cancer (OC) cells, and arrests in the G1 phase. Inhibitor treatment leads to enrichment of proteins associated with apoptosis and RNA degrad ...[more]

PMID: 33713600

Similar Datasets

Investigation of cellular response to the HSP90 inhibition in human cells through thermal proteome profiling

Project description:Heat shock proteins are responsible for protein folding in cells. HSP90 is one of the most important chaperones in human cells, and inhibiting HSP90 is a potential strategy for cancer therapy. Multiple HSP90 inhibitors have been in clinical trials. However, none of them has been approved for disease treatment due to unexpected cellular toxicity. Hence, a more comprehensive investigation of cellular responses to HSP90 inhibitors can aid in a better understanding of the molecular mechanisms of the cytotoxicity and side effects of these inhibitors. Protein thermal stability shift, which represents protein structure and interaction alterations, can provide another level of information complementary to commonly used abundance-based proteomics analysis. In this work, we systematically investigated cell responses to different HSP90 inhibitors through global quantification of protein thermal stability changes using thermal proteome profiling, together with quantification of protein abundance changes. Besides the targets and potential off-targets of the drugs, proteins with significant thermal stability changes under the HSP90 inhibition are found to be related to cell stress responses and the translation process. Moreover, proteins with thermal stability shifts under the inhibition are upstream of those with altered expressions. Importantly, the current results indicate that the inhibition of HSP90 results in a strong perturbance of cell transcription and translation processes. This study provides a different perspective to achieve a better understanding of cellular response to chaperone inhibition.

2023-05-10 | PXD037575 | Pride

Quantitative Proteomics Reveal the Role of Matrine in Lipid Metabolism

Project description:Hyperlipidemia (HLP) can lead to cardiovascular diseases (CVDs) and other urgent diseases, such as myocardial infarction (MI) and stroke. So, early therapy for HLP is necessary. As existing drugs to treat HLP could not achieve the ideal effect for some patients, we have to find new drugs for HLP treatment. More and more evidence has shown that matrine has the function in treating HLP, but the mechanism of matrine in treating HLP is still unknown. In this study, we investigated the mechanism of matrine in treating HLP by performing quantitative proteomics. We discovered that matrine can upregulate the gene transcription and expression of LDLR and improve the uptake of LDL in HepG2 cells. Results also showed that the upregulated LDLR mediated by matrine plays an important role in reversing disordered lipid metabolism in vivo. As the disordered lipid metabolism is related to the development of lung cancer and matrine has been reported to have the function of treating lung cancer, we explored whether the regulation of lipid metabolism mediated by metrine has effect on the development of lung cancer. Through performing quantitative proteomics in A549, we noticed that the dynamic proteins regulated by matrine mainly enriched in the pathways related to lipid metabolism. And the expression of LDLR was also promoted by matrine in A549 cells. As studies have found that upregulated and prolonged uptake of LDL is detrimental to breast cancer cells, we speculated matrine exerts its anti-lung cancer function through promoting the expression of LDLR.

2024-06-22 | PXD045502 | Pride

On the utility of ultrafast MS1-only proteomics in drug target discovery studies based on thermal proteome profiling method

Project description:Advances in high-throughput high-resolution mass spectrometry and the development of thermal proteome profiling approach (TPP) have made it possible to accelerate a drug target search. Since its introduction in 2014, TPP quickly became a method of choice in chemical proteomics for identifying drug-to-protein interactions on a proteome-wide scale and mapping the pathways of these interactions, thus, further elucidating the unknown mechanisms of action of a drug under study. However, the current TPP implementations based on tandem mass spectrometry (MS/MS), associated with employing lengthy peptide separation protocols and expensive labeling techniques for sample multiplexing limit the scaling of this approach for the ever growing variety of drug-to-proteome combinations at the faster pace. A variety of ultrafast proteomics methods have been developed in the last couple of years. Among them, DirectMS1 provides MS/MS-free quantitative proteome-wide analysis in a minute time scale, thus, opening the way for sample-hungry applications, such as TPP. In this work, we demonstrate the first implementation of the TPP approach using the ultrafast proteome-wide analysis based on DirectMS1. Using a drug topotecan, which is a known topoisomerase I inhibitor, the feasibility of the method for identifying drug targets at the whole proteome level was demonstrated for the ovarian cancer cell line.

2024-10-07 | PXD051712 | Pride

Identification of potential protein interaction candidates of MINCH in SGBS adipocytes using Thermal Proteome Profiling (TPP)

Project description:Here, we identified potential protein interaction partners of MINCH, as primary metabolite of the phthalate DEHP substitute DINCH, in the human SGBS adipocyte cell line. This study includes data on the thermal stability of proteins upon incubation of the cell lysates with 10 µM MINCH at day 4, an early, and day 12, the terminal day of adipocyte differentiation.

2025-08-05 | PXD059386 | Pride

Thermal proteome profiling of MMV897615

Project description:The target deconvolution of MMV897615 was evaluated using thermal proteome profiling (TPP), a chemical proteomics approach based on the stabilisation of protein targets upon ligand binding. In these TPP experiments we used a whole-cell strategy, exposing cells rather than lysates to the drug

2023-03-09 | PXD034937 | Pride

Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays

Project description:In this study, we developed a model system for the assessment of small molecule-protein interactions using intact cells treated with a commercially available highly specific mitogen-activated protein kinase (MEK) 1/2 inhibitor to prepare a set of unfractionated test samples labeled with tandem mass tags. Our objective was to improve qualitative and quantitative aspects of MS-TSA as well as its efficiency and accuracy. We evaluated individually and for the first time in combination ΦSDM, FAIMS, and SIILCC as an improved MS-based acquisition approach for thermal stability assays (iMAATSA). PSM-level filtering was preliminarily investigated as an approach to reduce melting curve variation and improve the accuracy of Tm measurements.

2023-05-10 | PXD034087 | Pride

Drug target deconvolution in Plasmodium falciparum using thermal proteomics profiling

Project description:Early identification of a compound’s mode of action can greatly benefit the discovery process. Thermal proteomics profiling (TPP) is a powerful, unbiased tool that can be used to identify potential ligands of protein targets. TPP takes advantage of the fact that a ligand binding to its target protein can significantly stabilise that protein, increasing its melting temperature (Tm). We previously optimised this technique for use in drug target deconvolution in the kinetoplastid parasite, Leishmania donovani1 and here report the optimisation and validation of TPP in the malaria-causing parasite P. falciparum.

2022-10-13 | PXD025182 | Pride

Withanolide analogues disrupt a leukemic dependency on cholesterol transport by inhibiting the oxysterol-binding protein OSBP (TPP)

Project description:Metabolic alterations in cancers precipitate in associated dependencies that can be therapeutically exploited. To meet this goal, natural product inspired small molecules can provide a resource of underexplored chemotypes. We identify W7, a synthetic withanolide analog with pronounced anti-leukemic properties via orthogonal chemical screening. Through multi-omics profiling (including expression proteomics) and genome-scale CRISPR/Cas9 screens, we identify that W7 disrupts Golgi homeostasis via a mechanism that requires active PI4P signaling at the ER-Golgi membrane interface. Thermal proteome profiling and genetic validation studies reveal the oxysterol-binding protein OSBP as the direct and phenotypically relevant target of W7. Collectively, our data reaffirms sterol transport as a therapeutically actionable dependency in leukemia and motivate ensuing translational investigation via the probe-like compound W7.

2024-06-27 | PXD040692 | Pride

Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays

Project description:Mass spectrometry (MS)-based thermal stability assays have recently emerged as one of the most promising solutions for the identification of protein-ligand interactions. Here, we have investigated eight combinations of several recently introduced MS-based advancements, including the Phase-Constrained Spectral Deconvolution Method, Field Asymmetric Ion Mobility Spectrometry, and the implementation of a carrier sample as improved MS-based acquisition approaches for thermal stability assays (iMAATSA). We used intact Jurkat cells treated with a commercially available MEK inhibitor, followed by heat treatment, to prepare a set of unfractionated isobarically-labeled proof-of-concept samples to compare the performance of eight different iMAATSAs. Finally, the best-performing iMAATSA was compared to a conventional approach and evaluated in a fractionation experiment. Improvements of up to 82% and 86% were demonstrated in protein identifications and high-quality melting curves, respectively, over the conventional approach in the proof-of-concept study, while an approximately 12% improvement in melting curve comparisons was achieved in the fractionation experiment.

2023-05-10 | PXD040284 | Pride

An Anti-Cancer Gold(III)-Activated Porphyrin Scaffold that Covalently Modifies Protein Cysteine Thiols

Project description:Cysteine thiols of many cancer-associated proteins are attractive targets of anti-cancer agents. Herein, we unequivocally demonstrate a distinct thiol-targeting property of gold(III) mesoporphyrin IX dimethyl ester (AuMesoIX) and its anti-cancer activities. While the binding of cysteine thiols with metal complexes usually occurs via M–S bond formation, AuMesoIX is unique in that the meso-carbon atom of the porphyrin ring is activated by the gold(III) ion to undergo nucleophilic aromatic substitution with thiols. AuMesoIX was shown to modify reactive cysteine residues and inhibit the activities of anti-cancer protein targets including thioredoxin, peroxiredoxin, and deubiquitinases. Treatment of cancer cells with AuMesoIX resulted in the formation of gold-bound sulfur-rich protein aggregates, oxidative stress-mediated cytotoxicity, and accumulation of ubiquitinated proteins. Importantly, AuMesoIX exhibited effective anti-tumor activity in mice. Our study has uncovered a gold(III)-induced ligand scaffold reactivity for thiol targeting that can be exploited for anti-cancer applications.

2021-09-08 | PXD016875 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data